Tecentriq® (atezolizumab) – New indication
March 18, 2019 - Genentech announced the FDA approval of Tecentriq (atezolizumab), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Download PDF
